

参考文献

- Doyle T, Dunn D, Ceccherini-Silberstein F, et al. Integrase inhibitor (INI) genotypic resistance in treatment-naïve and raltegravir-experienced patients infected with diverse HIV-1 clades. *J Antimicrob Chemother.* 2015;70:3080-3086.
- Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. *Lancet.* 1999;353:2195-2199.
- Emu B, DeJesus E, Berhe M, et al. Ibalizumab efficacy and safety through 48 weeks of treatment: results of an expanded access protocol (TMB-311). ID Week 2019. October 2-6; Washington, DC. Abstract 661.
- Emu B, Fessel WJ, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. *N Engl J Med.* 2018 Aug 16;379(7):645-654.
- Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. *Lancet Infect Dis.* 2013;13(7):587-596
- Eron JJ, Orkin C, Cunningham D, et al. Week 96 Efficacy and Safety Results of the Phase 3, Randomized EMERALD Trial to Evaluate Switching From Boosted-Protease Inhibitors Plus Emtricitabine/Tenofovir Disoproxil Fumarate Regimens to the Once Daily, Single-Tablet Regimen of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Treatment-Experienced, Virologically-Suppressed Adults Living With HIV-1. *Antiviral Res.* 2019;170:104543.
- Eron JJ, Orkin C, Molina JM, et al. Analysis of HIV patients switching to D/C/F/T by prior ARV treatment experience. CROI 2018. March 4-7, 2018. Boston, MA. Abstract 502.
- Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viremia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials. *Lancet.* 2010;375:396-407.
- European AIDS Clinical Society. EACS Guidelines, version 10.0. November 2019. Available at: <https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>. Accessed April 13, 2020.
- Fabbiani M, Gagliardini R, Ciccarelli N, et al. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. *J Antimicrob Chemother.* 2018;73(7):1955-1964.